Skip to content
value.today

Rapport Therapeutics, Inc.: insider trading

139 trades by 15 directors, officers and 10% owners since 2024, from their SEC Form 4 and 5 filings.

Bought, 12 months
$22.0 M
11 purchases by 7 insiders
Sold, 12 months
$46.7 M
66 sales by 6 insiders
Bought, 3 months
$22.0 M
11 purchases
Sold, 3 months
$4.5 M
14 sales

Insider buying and selling by month

Open-market purchases and sales by value, last three years.

$22.0 M-$18.7 M$0Jun 2024: bought $9.5 M (5 trades), sold $0 (0 trades)Jun 24Jul 2024: bought $1.1 M (12 trades), sold $0 (0 trades)Mar 2025: bought $162 K (3 trades), sold $92 K (1 trades)Apr 2025: bought $0 (0 trades), sold $81 K (1 trades)AprMay 2025: bought $0 (0 trades), sold $81 K (1 trades)Jun 2025: bought $0 (0 trades), sold $94 K (1 trades)Jul 2025: bought $0 (0 trades), sold $119 K (1 trades)JulAug 2025: bought $0 (0 trades), sold $127 K (2 trades)Sep 2025: bought $1.6 M (4 trades), sold $2.4 M (7 trades)Oct 2025: bought $0 (0 trades), sold $501 K (6 trades)OctNov 2025: bought $0 (0 trades), sold $640 K (7 trades)Dec 2025: bought $0 (0 trades), sold $861 K (10 trades)Jan 2026: bought $0 (0 trades), sold $513 K (4 trades)Jan 26Feb 2026: bought $0 (0 trades), sold $567 K (7 trades)Mar 2026: bought $0 (0 trades), sold $643 K (4 trades)Apr 2026: bought $0 (0 trades), sold $18.7 M (6 trades)AprMay 2026: bought $0 (0 trades), sold $17.2 M (4 trades)Jun 2026: bought $0 (0 trades), sold $743 K (6 trades)Jul 2026: bought $0 (0 trades), sold $421 K (4 trades)JulAug 2026: bought $0 (0 trades), sold $5.9 M (10 trades)Sep 2026: bought $0 (0 trades), sold $793 K (7 trades)Oct 2026: bought $22.0 M (11 trades), sold $208 K (3 trades)Oct
Bought (open market)Sold (open market)Hover a month for the totals

Insiders (15)

Each insider's latest direct holding and their open-market trades of the last 12 months, most recent first.

Rapport Therapeutics, Inc. insiders
InsiderShares owned directlyBought, 12 mSold, 12 mLatest trade
Third Rock Ventures V, L.P.Director, 10% owner6.52 M—$6.1 M
James HealyDirector—$20.4 M—
Ramiro SanchezDirector3,600$98 K—
John MaraganoreDirector—$249 K—
Paul M. SilvaDirector—$100 K—
Steven M. PaulDirector—$974 K—
Wendy B. YoungDirector13,289$100 K—
Abraham CeesayChief Executive Officer, Director450,035—$5.7 M
Troy A. IgnelziChief Financial Officer15,500$144 K—
Cheryl GaultChief Operating Officer139,914—$1.2 M
Krishnaswamy YeleswaramChief Development Officer195,862—$4.5 M
Third Rock Ventures VI, L.P.10% owner6.43 M—$28.3 M
David BredtChief Scientific Officer393,075—$927 K
Reid M. HuberDirector20,400——
Robert Nelsen10% owner———

Trades#

Rapport Therapeutics, Inc.: insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed James HealyDirectorBuyindirect+952,380$21.00$20.0 M2.82 MForm 4
filed James HealyDirectorBuyindirect+6,395$21.00$134 K17,990Form 4
filed James HealyDirectorBuyindirect+3,772$21.00$79 K14,924Form 4
filed James HealyDirectorBuyindirect+6,933$21.00$146 K25,267Form 4
filed Ramiro SanchezDirectorBuy+3,600$27.35$98 K3,600Form 4
filed Wendy B. YoungDirectorBuy+3,789$26.39$100 K13,289Form 4
filed John MaraganoreDirectorBuyindirect+8,239$26.38$217 K8,239Form 4
filed Steven M. PaulDirectorBuyindirect+35,714$27.28$974 K77,380Form 4
filed Paul M. SilvaDirectorBuyindirect+3,680$27.07$100 K3,680Form 4
filed John MaraganoreDirectorBuyindirect+1,172$26.92$32 K9,411Form 4
filed Troy A. IgnelziChief Financial OfficerBuy+5,500$26.10$144 K15,500Form 4
filed Steven M. PaulDirectorBuyindirect+28,284$24.50$693 K28,284Form 4
filed Reid M. HuberDirectorBuy+20,400$24.48$499 K20,400Form 4
filed Steven M. PaulDirectorBuyindirect+13,382$24.97$334 K41,666Form 4
filed Wendy B. YoungDirectorBuy+3,500$22.60$79 K9,500Form 4
filed Troy A. IgnelziChief Financial OfficerBuy+100$9.980$99810,000Form 4
filed Troy A. IgnelziChief Financial OfficerBuy+9,900$10.10$100 K9,900Form 4
filed Wendy B. YoungDirectorBuy+6,000$10.21$61 K6,000Form 4
filed James HealyDirectorBuyindirect+3,538$23.08$82 K28,993Form 4
filed James HealyDirectorBuyindirect+3,565$24.21$86 K32,558Form 4
filed James HealyDirectorBuyindirect+4,544$25.02$114 K37,102Form 4
filed James HealyDirectorBuyindirect+2,559$26.06$67 K39,661Form 4
filed James HealyDirectorBuyindirect+3,799$23.08$88 K21,660Form 4
filed James HealyDirectorBuyindirect+3,828$24.21$93 K25,488Form 4
filed James HealyDirectorBuyindirect+4,878$25.02$122 K30,366Form 4
filed James HealyDirectorBuyindirect+2,748$26.06$72 K33,114Form 4
filed James HealyDirectorBuyindirect+3,630$23.08$84 K29,908Form 4
filed James HealyDirectorBuyindirect+3,657$24.21$89 K33,565Form 4
filed James HealyDirectorBuyindirect+4,661$25.02$117 K38,226Form 4
filed James HealyDirectorBuyindirect+2,625$26.06$68 K40,851Form 4
filed James HealyDirectorBuyindirect+470,589$17.00$8.0 M1.86 MForm 4
filed James HealyDirectorBuyindirect+18,641$17.00$317 K18,641Form 4
filed James HealyDirectorBuyindirect+17,861$17.00$304 K17,861Form 4
filed James HealyDirectorBuyindirect+26,278$17.00$447 K26,278Form 4
filed James HealyDirectorBuyindirect+25,455$17.00$433 K25,455Form 4

Source: SEC Forms 4 and 5. A trade under a 10b5-1 plan was scheduled in advance. For information only; not investment advice